Therapeutic Biomarkers of EGFR-TKI

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 11, 2012, Pages 1613-1617

  Seike, Masahiro ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Biomarker; EGFR mutation; EGFR TKI resistance; Lung cancer

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN RECEPTOR;

DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE DELETION; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 84872696867     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004. (Pubitemid 38637993)
2. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500, 2004. (Pubitemid 38720929)
3. Mitsudomi T, Kosaka T and Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11(3): 190-198, 2006. (Pubitemid 44087117)
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25): 2380-2388, 2010.
5. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128, 2010.
6. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8): 735-742, 2011.
7. Keam B, Kim DW, Park JH, et al: Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 30(15s): abstr 7566, 2012.
8. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8): 786-792, 2005. (Pubitemid 40271173)
9. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827): 1039-1043, 2007. (Pubitemid 46799492)
10. Yano S, Wang W, Li Q, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22): 9479-9487, 2008.
11. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34): 4702-4711, 2008.
12. Regales L, Gong Y, Shen R, et al: Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119(10): 3000-3010, 2009.
13. Chih-Hsin Yang J, Martin HS, Yamamoto N, et al: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30(Suppl): abstr LBA7500, 2012.
14. Hata A, Katakami N, Yoshioka H, et al: Rebiopsy of nonsmall cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and-negative populations. J Clin Oncol 30(Suppl): abstr 7528, 2012.
15. Schiller JH, Akerley WL, Brugger WD, et al: Results from ARQ 197-209: A global randomized placebo-controlled phase H clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28(18s): abstr LBA7502, 2010.
16. Bivona TG, Hieronymus H, Parker J, et al: FAS and NF-κB signaling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339): 523-526, 2011.
17. Cheung HW, Du J, Boehm JS, et al: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1(7): 608-625, 2011.
18. Yamaguchi T, Yanagisawa K, Sugiyama R, et al: NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21(3): 348-361, 2012.
19. Kokubo Y, Gemma A, Noro R, et al: Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92(9): 1711-1719, 2005. (Pubitemid 40756483)
20. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75): 75ra26, 2011.
21. Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63(2): 219-226, 2009.
22. Witta SE, Gemmill RM, Hirsch FR, et al: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2): 944-950, 2006. (Pubitemid 43165962)
23. Sharma SV, Lee DY, Li B, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1): 69-80, 2010.
24. Seike M, Goto A, Okano T, et al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106(29): 12085-12090, 2009.
25. Garofalo M, Romano G, Di Leva G, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1): 74-82, 2011.